Journal Information
Vol. 100. Issue 3.
Pages 241-243 (April 2009)
Share
Share
Download PDF
More article options
Vol. 100. Issue 3.
Pages 241-243 (April 2009)
Clinical science letters
Full text access
Intertriginous Rash Caused by Pegylated Liposomal Doxorubicin
Visits
5982
B. Monteagudoa,
Corresponding author
benims@hotmail.com

Correspondence: C/ Alegre, 83-85, 3.°A, 15401 Ferrol, A Coruña, Spain.
, F.J. Afonso-Afonsob, M. Cabanillasa, M.M. Used-Aznarc
a Servicio de Dermatología, Complejo Hospitalario Arquitecto Marcide-Novoa Santos, Ferrol, A Coruña, Spain
b Servicio de Oncología, Complejo Hospitalario Arquitecto Marcide-Novoa Santos, Ferrol, A Coruña, Spain
c Servicio de Anatomía Patológica, Complejo Hospitalario Arquitecto Marcide-Novoa Santos, Ferrol, A Coruña, Spain
This item has received
Article information
Full text is only aviable in PDF
References
[1.]
D.N. Waterhouse, P.G. Tardi, L.D. Mayer, M.B. Bally.
A compa rison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles.
DrugSaf, 24 (2001), pp. 903-920
[2.]
D. Lorusso, A. Di Stefano, V. Carone, A. Fagotti, S. Pisconti, G. Scambia.
Pegylated liposomal doxorubicin-related pal-mar-plantar erythrodysesthesia (’hand-foot’ syndrome).
Ann Oncol, 18 (2007), pp. 1159-1164
[3.]
L. Hueso, O. Sanmartín, E. Nagore, R. Botella Estrada, C. Requena, B. Llombart, et al.
Eritema acral inducido por quimioterapia: estudio clínico e histopatológico de 44 casos.
Actas Dermosifiliogr, 99 (2008), pp. 281-290
[4.]
R.J. Kim, G. Peterson, B. Kulp, K.M. Zanotti, M. Markman.
Skin toxicity associated with pegylated liposomal doxorubicin (40 mg/m2) in the treatment of gynecologic cancers.
Gynecol Oncol, 97 (2005), pp. 374-378
[5.]
M. Lotem, A. Hubert, O. Lyass, M.A. Goldenhersh, A. Ingber, T. Peretz, et al.
Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin.
Arch Dermatol, 136 (2000), pp. 1475-1480
[6.]
H. Skelton, J. Linstrum, K. Smith.
Host-vs.-altered-host eruptions in patients on liposomal doxorubicin.
J Cutan Pathol, 29 (2002), pp. 148-153
[7.]
J.C. English III, R. Toney, J.W. Patterson.
Intertriginous epidermal dysmaturation from pegylated liposomal doxorubicin.
J Cutan Pathol, 30 (2003), pp. 591-595
[8.]
G.E. Korver, H. Ronald, M.J. Petersen.
An intertrigo-like eruption from pegylated liposomal doxorubicin.
J Drugs Dermatol, 5 (2006), pp. 901-902
[9.]
A. Saini, A. Berruti, P. Sperone, R. Bitossi, M. Tampellini, L. Dogliatti, et al.
Recall inflammatory skin reaction after use of pegylated liposomal doxorubicin in site of previous drug extravasation.
Lancet Oncol, 7 (2006), pp. 186-187
[10.]
E. Castaño, J.L. Rodríguez Peralto, F. López Ríos, C. Gómez, M. Zimmermann, L. Iglesias Díez.
Keratinocyte dysplasia: an usual finding after transplantation or chemotherapy.
J Cutan Pathol, 29 (2002), pp. 579-584
[11.]
F.M. Cady, R. Kneuper Hall, J.S. Metcalf.
Histologic patterns of polyethylene glycol-liposomal doxorubicin-related cutaneous eruptions.
Am J Dermatopathol, 28 (2006), pp. 168-172
Copyright © 2009. Academia Española de Dermatología y Venereología and Elsevier España, S.L.
Idiomas
Actas Dermo-Sifiliográficas
Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?